Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas

Authors:

Abstract
First-line systemic treatment for metastatic soft-tissue sarcomas (STSs) has hardly improved over 40 years, doxorubicin being the standard approach; no significant overall survival (OS) benefit has been demonstrated with combination schemes.1-5 Nevertheless, anthracycline-based polychemotherapy regimens can be recommended if the aim is surgical resection or fast palliation, since they offer a significantly higher probability of tumor shrinkage.6

This publication has 34 references indexed in Scilit: